Pernix Therapeutics (PTX) – Analyst PT Change
-
Needham & Company Reiterates Stong Buy Ahead of Pernix Therapeutics' (PTX) 4Q Release
-
Pernix Therapeutics (PTX) PT Trimmed to $14 at Brean Capital Amid Weak Q2
-
-
-
-
-
-
-
-
-
Back to PTX Stock Lookup